A PHASE 1/2 STUDY EVALUATING GENE THERAPY BY TRANSPLANTATION OF AUTOLOGOUS CD34+ STEM CELLS MODIFIED EX VIVO USING PRIME EDITING (PM359) IN PARTICIPANTS WITH AUTOSOMAL RECESSIVE CHRONIC GRANULOMATOUS DISEASE DUE TO MUTATIONS IN THE NCF1 GENE

Registry ID

PRIME-0101

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

PRIME MEDICINE, INC.

Start date

2024-08-30

Last update

2024-05-24

Conditions

• GRANULOMATOSIS

Related clinical trials

• "ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF RELAPSING, NON-SEVERE, GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) (ABROGATE)."

View on source registry